Dr Tanya Holt is an experienced radiation oncologist at Icon Cancer Centre Greenslopes, bringing over 15 years’ experience in the diagnosis and treatment of genitourinary cancers, anorectal cancers and palliative radiation therapy. She obtained her Bachelor of Medicine, Bachelor of Surgery (MBBS) at Adelaide University and subsequently completed specialist oncology training in Brisbane. Dr Holt became a fellow of the Royal Australian and New Zealand College of Radiologists (FRANZCR) before joining the Princess Alexandra Hospital as a consultant radiation oncologist at the Mater Centre site in 2006. She holds current appointments as senior lecturer at the University of Queensland and RANZCR examiner.

Dr Holt maintains an active interest in education, research and clinical trials, participating in several key studies and trials investigating radiation therapy treatments for prostate cancer, bladder cancer and palliative care. As an examiner for the RANZCR, she has been heavily involved in the development of the Australian and New Zealand Radiation Oncology Training Programme since the curriculum inception in 2006. Dr Holt is an active member of several leading cancer trial groups including Trans Tasman Radiation Oncology Group (TROG), Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) and International Society of Palliative Radiation Oncology (SPRO). In collaboration with TROG, she has acted as lead Australian investigator on a number of published international palliative radiation therapy trials. She is the current chairperson of the Faculty of Radiation Oncology Genitourinary Group, a group with a strong focus on education and advocacy.

Dr Holt believes in the holistic treatment of palliative patients and established the first Australian Rapid Response Palliative Radiation Clinic in 2010. She subsequently established a pathway and training for the first Australian advanced practice palliative radiation therapist. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in prostate, bladder, anorectal and skin cancers, and stereotactic and palliative radiation therapy.